Clinical pharmacology of tocilizumab for the treatment of patients with rheumatoid arthritis

Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy

(2014) Norihiro Nishimoto et al.   Modern Rheumatology

Disease–Drug–Drug Interaction Involving Tocilizumab and Simvastatin in Patients With Rheumatoid Arthritis

(2011) C Schmitt et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

(2010) J. S. Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Treating rheumatoid arthritis to target: recommendations of an international task force

(2010) J. S. Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative

(2010) Daniel Aletaha et al.   ARTHRITIS AND RHEUMATISM

Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu

(2010) Joel M. Kremer et al.   ARTHRITIS AND RHEUMATISM

Strategies after the failure of the first anti-tumor necrosis factor α agent in rheumatoid arthritis

(2010) Charalampos Papagoras et al.   AUTOIMMUNITY REVIEWS

Optimising the strategy of care in early rheumatoid arthritis

(2010) James Dale et al.   BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY

Correlation of a multi-cytokine panel with clinical disease activity in patients with rheumatoid arthritis

(2010) Nataliya Milman et al.   CLINICAL BIOCHEMISTRY

Update on the use of conventional disease-modifying antirheumatic drugs in the management of rheumatoid arthritis

(2010) Michael G Feely et al.   CURRENT OPINION IN RHEUMATOLOGY

Role for interleukin-6 in structural joint damage and systemic bone loss in rheumatoid arthritis

(2010) Benoit Le Goff et al.   JOINT BONE SPINE

The environment, geo-epidemiology, and autoimmune disease: Rheumatoid arthritis

(2010) Gabriel J. Tobón et al.   JOURNAL OF AUTOIMMUNITY

Population Pharmacokinetic Analysis of Tocilizumab in Patients With Rheumatoid Arthritis

(2010) Nicolas Frey et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Improving the Routine Management of Rheumatoid Arthritis: The Value of Tight Control

(2010) P. J. MEASE   JOURNAL OF RHEUMATOLOGY

Kinase inhibitors attract attention as oral rheumatoid arthritis drugs

(2010) Alisa Opar   NATURE REVIEWS DRUG DISCOVERY

A Multitude of Kinases—Which are the Best Targets in Treating Rheumatoid Arthritis?

(2010) Tamsin M. Lindstrom et al.   RHEUMATIC DISEASE CLINICS OF NORTH AMERICA

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

(2009) G. Jones et al.   ANNALS OF THE RHEUMATIC DISEASES

Rapid and sustained improvement in bone and cartilage turnover markers with the anti–interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: Results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone

(2009) Patrick Garnero et al.   ARTHRITIS AND RHEUMATISM

Blockade of Interleukin 6 Signaling Induces Marked Neutropenia in Patients with Rheumatoid Arthritis

(2009) I. NAKAMURA et al.   JOURNAL OF RHEUMATOLOGY

Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review

(2009) Andrea Rubbert-Roth et al.   ARTHRITIS RESEARCH & THERAPY

Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases

(2009) Sherine E Gabriel et al.   ARTHRITIS RESEARCH & THERAPY

Tocilizumab: The first interleukin-6-receptor inhibitor

(2008) Anthony Sebba   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study

(2008) N Nishimoto et al.   ANNALS OF THE RHEUMATIC DISEASES

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

(2008) P. Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study

(2008) Mark C. Genovese et al.   ARTHRITIS AND RHEUMATISM

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis

(2008) Kenneth G. Saag et al.   ARTHRITIS AND RHEUMATISM

Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease

(2008) N. Nishimoto et al.   BLOOD

Anti-IL-6 receptor antibody increases blood IL-6 level via the blockade of IL-6 clearance, but not via the induction of IL-6 production

(2008) Yasushi Uchiyama et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

(2008) Josef S Smolen et al.   LANCET

Influence of humanized anti-IL-6R antibody, tocilizumab on the activity of soluble gp130, natural inhibitor of IL-6 signaling

(2008) Misato Hashizume et al.   RHEUMATOLOGY INTERNATIONAL